Extremity Radioactive Iodine Uptake on Post-therapeutic Whole Body Scan in Patients with Differentiated Thyroid Cancer

Authors

  • Anri Inaki Department of Nuclear Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan
  • Ayane Toratani Department of Nuclear Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan
  • Daiki Kayano Department of Nuclear Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan
  • Junichi Taki Department of Nuclear Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan
  • Seigo Kinuya Department of Nuclear Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan
Abstract:

Objective(s): We investigated a frequency of lower extremity uptake on the radioactive iodine (RAI) whole body scan (WBS) after RAI treatment in patients with differentiated thyroid cancer, in order to retrospectively examine whether or not the frequency was pathological. Methods: This retrospective study included 170 patients with thyroid cancer, undergoing RAI treatment. Overall, 99r (58%) and 71 (42%)patients received single and multiple RAI treatments, respectively. Post-therapeutic WBS was acquired after 3 days of RAI administration. For patients with multiple RAI treatments, the WBS of their last RAI treatment was evaluated. Lower extremity uptake on post-therapeutic WBS was classified into 3 categories: bilateral femoral uptake (type A), bilateral femoral and tibia uptake (type B), and uptake in bilateral upper and lower extremities (type C). Then, the patients with RAI uptake in the lower extremities on WBS were analyzed with clinical parameters. Results: Overall, 99 patients (58%) had the extremity uptake on their posttherapeutic RAI WBS. As the results indicated, 42 ,53, and 4 patients had type A, type B, and type C uptakes, respectively. Lower extremity uptake was significantly associated with younger age, not only in subjects with multiple RAI treatments but also in all the patients (P

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

extremity radioactive iodine uptake on post-therapeutic whole body scan in patients with differentiated thyroid cancer

objective(s): we investigated a frequency of lower extremity uptake on the radioactive iodine (rai) whole body scan (wbs) after rai treatment in patients with differentiated thyroid cancer, in order to retrospectively examine whether or not the frequency was pathological. methods: this retrospective study included 170 patients with thyroid cancer, undergoing rai treatment. overall, 99r (58%) an...

full text

Post-Therapeutic I-131 Whole Body Scan in Patients with Differentiated Thyroid Cancer

Therapy with radioiodine (I-131) has been used for patients with well-differentiated thyroid cancer such as papillary and follicular thyroid carcinoma to ablate normal thyroid tissue or to treat metastatic lesions. The improvement of survival rates and decrease of recurrence rates after I-131 therapy has been documented by retrospective studies (Mazzaferri & Jhiang, 1994; Samaan et al., 1992). ...

full text

Nuclear Imaging in Patients with Differentiated Thyroid Cancer and Negative Radioactive Io-dine Scan

Background: Thyroid cancer is the most common endocrine malignancy in the world; however, these patients usually experience a high survival rate if they receive appropriate and timely treatment. Meanwhile, patients classified as having differentiated thyroid cancer with high thyroglobulin and negative iodine scan [Differentiated thyroid cancer with thyroglobulin elevation and negative iodine sc...

full text

Comparison of pretreatment and post-treatment whole body scan results (WBS) with I-131 in 94 patients with differentiated Thyroid cancer (DTC) [Persian]

Discrepancy between pre & post treatment WBSs (Low dose & high dose, respectively) is reported. The aim of this study was determination the post-treatment WBS role in the diagnosis of lesions not identified by the pretreatment one. In this study 94 patients (pts) with DTC were evaluated. The results of pre & post treatment WBSs were compared. Overall, 25.6% of pts revealed more positive l...

full text

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer

Recent Phase III data presented at the American Society of Clinical Oncology (ASCO) 2013 annual conference by Brose et al led to the US Food and Drug Administration (FDA) approval of sorafenib for the treatment of well-differentiated radioactive iodine-resistant metastatic thyroid cancer. This is the second drug in 40 years to be FDA approved for this indication. Recent reviews and a meta-analy...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 3  issue 1

pages  26- 34

publication date 2015-01-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023